Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision label updated to v3.6.5, replacing the previous v3.6.4, signaling a minor software update of the site interface. This change is metadata about the page rather than alterations to study content or eligibility information.SummaryDifference0.0%

- Check25 days agoChange DetectedInvestigator Inquiry Form was removed from the page. Users can still contact the study team using the listed contacts and locations.SummaryDifference0.0%

- Check32 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing the previous v3.6.3. This reflects a minor system update to the page rather than a change to the study details.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page's revision indicator was bumped from v3.6.2 to v3.6.3, signaling a minor update to the study record.SummaryDifference0.0%

- Check61 days agoChange DetectedFooter revision tag updated from v3.6.0 to v3.6.2, indicating the page has been rebuilt or updated to a newer version.SummaryDifference0.0%

- Check76 days agoChange DetectedThe study details page adds a recruitment status indicator stating no participants are being recruited and introduces new guidance sections for reading the study record, common questions, and how to join a study. The Intervention/Treatment label is standardized, and a new site revision tag (v3.6.0) is shown, while the older revision tag is removed.SummaryDifference0.3%

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.